β-Lactam-Induced Cell Envelope Adaptations, Not Solely Enhanced Daptomycin Binding, Underlie Daptomycin-β-Lactam Synergy in Methicillin-Resistant Staphylococcus aureus.

Antimicrobial Agents and Chemotherapy
Cassandra LewW E Rose

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a serious clinical threat due to innate virulence properties, high infection rates, and the ability to develop resistance to multiple antibiotics, including the lipopeptide daptomycin (DAP). The acquisition of DAP resistance (DAP-R) in MRSA has been linked with several characteristic alterations in the cell envelope. Clinical treatment of DAP-R MRSA infections has generally involved DAP-plus-β-lactam combinations, although definable synergy of such combinations varies in a strain-dependent as well as a β-lactam-dependent manner. We investigated distinct β-lactam-induced cell envelope adaptations of nine clinically derived DAP-susceptible (DAP-S)/DAP-R strain pairs following in vitro exposure to a panel of six standard β-lactams (nafcillin, meropenem, cloxacillin, ceftriaxone, cefaclor, or cefoxitin), which differ in their penicillin-binding protein (PBP)-targeting profiles. In general, in both DAP-S and DAP-R strains, exposure to these β-lactams led to (i) a decreased positive surface charge; (ii) decreased cell membrane (CM) fluidity; (iii) increased content and delocalization of anionic phospholipids (i.e., cardiolipin), with delocalization being more pronounced in DAP-R s...Continue Reading

References

Jul 1, 1987·Antimicrobial Agents and Chemotherapy·N E AllenW E Alborn
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Kenneth H Rand, Herbert J Houck
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Oct 20, 2007·Biochimica Et Biophysica Acta·Walter R P ScottSuzana K Straus
Jan 13, 2011·Biochimica Et Biophysica Acta·Jawad K MuraihMichael Palmer
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Abhay DhandGeorge Sakoulas
Dec 12, 2012·Annals of the New York Academy of Sciences·Arnold S BayerHans-Georg Sahl
Dec 21, 2012·Antimicrobial Agents and Chemotherapy·Nagendra N Mishra, Arnold S Bayer
Sep 5, 2013·Antimicrobial Agents and Chemotherapy·Soo-Jin YangArnold S Bayer
Nov 5, 2013·International Journal of Antimicrobial Agents·Viviana CafisoStefania Stefani
Nov 3, 2016·Cold Spring Harbor Perspectives in Medicine·William R MillerCesar A Arias
Oct 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Anna MüllerLeendert W Hamoen
Jan 31, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Soo-Jin YangArnold S Bayer
Feb 5, 2019·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Daisuke OnoKazuhiro Tateda
Feb 10, 2019·Nature Reviews. Microbiology·Nicholas A TurnerVance G Fowler
Feb 28, 2019·Proceedings of the National Academy of Sciences of the United States of America·Jhih-Hang JiangAnton Y Peleg
Aug 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sarah C J JorgensenMichael J Rybak

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence microscopy
confocal microscopy

Software Mentioned

Huygens
ImageJ

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.